BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1141 related articles for article (PubMed ID: 34798898)

  • 21. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
    Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 23. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
    Lee JC; Mehdizadeh S; Smith J; Young A; Mufazalov IA; Mowery CT; Daud A; Bluestone JA
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33008914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
    Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
    Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
    Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
    J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
    Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
    Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
    Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
    PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.
    Toker A; Nguyen LT; Stone SC; Yang SYC; Katz SR; Shaw PA; Clarke BA; Ghazarian D; Al-Habeeb A; Easson A; Leong WL; McCready DR; Reedijk M; Guidos CJ; Pugh TJ; Bernardini MQ; Ohashi PS
    Clin Cancer Res; 2018 Nov; 24(22):5685-5696. PubMed ID: 30065096
    [No Abstract]   [Full Text] [Related]  

  • 30. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
    Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
    Pham CD; Flores C; Yang C; Pinheiro EM; Yearley JH; Sayour EJ; Pei Y; Moore C; McLendon RE; Huang J; Sampson JH; Wechsler-Reya R; Mitchell DA
    Clin Cancer Res; 2016 Feb; 22(3):582-95. PubMed ID: 26405194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1
    Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
    Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Qa-1
    Zhang X; Sabio E; Krishna C; Ma X; Wang J; Jiang H; Havel JJ; Chan TA
    Mol Cancer Res; 2021 Jun; 19(6):1076-1084. PubMed ID: 33674442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
    Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
    Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells.
    Vick SC; Kolupaev OV; Perou CM; Serody JS
    J Immunol; 2021 Nov; 207(10):2598-2607. PubMed ID: 34607937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer.
    Gadwa J; Bickett TE; Darragh LB; Knitz MW; Bhatia S; Piper M; Van Court B; Bhuvane S; Nguyen D; Nangia V; Kleczko EK; Nemenoff RA; Karam SD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
    Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
    Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
    Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clever-1/stabilin-1 controls cancer growth and metastasis.
    Karikoski M; Marttila-Ichihara F; Elima K; Rantakari P; Hollmén M; Kelkka T; Gerke H; Huovinen V; Irjala H; Holmdahl R; Salmi M; Jalkanen S
    Clin Cancer Res; 2014 Dec; 20(24):6452-64. PubMed ID: 25320356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
    Hashemi V; Maleki LA; Esmaily M; Masjedi A; Ghalamfarsa G; Namdar A; Yousefi M; Yousefi B; Jadidi-Niaragh F
    Int Immunopharmacol; 2020 Jan; 78():106087. PubMed ID: 31841758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.